Leap Therapeutics Inc
LPTX0.290USD
-0.032-9.83%
收盘 09/19, 16:00（美东）报价延迟15分钟
12.01M总市值
亏损市盈率 TTM
关于 Leap Therapeutics Inc 公司
Leap Therapeutics, Inc. 是一家生物制药公司。该公司专注于开发靶向和免疫肿瘤疗法。其高级临床候选药物 DKN-01 是一种针对 Dickkopf 相关蛋白 1 (DKK1) 蛋白的人源化单克隆抗体。DKK1 也是 CKAP4/PI3K/AKT 信号的调节剂。DKN-01 正在针对食管胃癌、妇科癌和结直肠癌患者进行开发。其第二个临床阶段项目是 FL-301，一种针对 Claudin18.2 的人源化单克隆抗体，正在针对胃癌和胰腺癌患者进行开发。该公司还有两个临床前抗体项目，FL-302 和 FL-501。FL-302 是一种 Claudin18.2/CD137（也称为 4-1BB）双特异性抗体，目前处于临床前开发阶段。 FL-501 是一种处于临床前开发阶段的单克隆抗体，其目标为生长和分化因子 15 (GDF15)，这是一种在响应各种压力时产生的高水平细胞因子。
公司简介
公司代码LPTX
公司名称Leap Therapeutics Inc
上市日期Jan 24, 2017
CEOMr. Douglas E. (Doug) Onsi
员工数量52
证券类型Ordinary Share
年结日Jan 24
公司地址47 Thorndike St, Suite B1-1
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02141
电话16177140360
网址https://www.leaptx.com/
公司代码LPTX
上市日期Jan 24, 2017
CEOMr. Douglas E. (Doug) Onsi
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
108.28K
+2.01%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Chairman of the Board
Chairman of the Board
23.05K
+10.21%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
-60.52%
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
--
--
Ms. Patricia (Patty) Martin
Ms. Patricia (Patty) Martin
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
108.28K
+2.01%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Chairman of the Board
Chairman of the Board
23.05K
+10.21%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
-60.52%
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Gilead Sciences Inc
12.84%
683 Capital Management LLC
3.48%
Acadian Asset Management LLC
2.99%
Beigene Ltd
2.93%
The Vanguard Group, Inc.
2.80%
其他
74.96%
持股股东
持股股东
占比
Gilead Sciences Inc
12.84%
683 Capital Management LLC
3.48%
Acadian Asset Management LLC
2.99%
Beigene Ltd
2.93%
The Vanguard Group, Inc.
2.80%
其他
74.96%
股东类型
持股股东
占比
Corporation
15.77%
Investment Advisor
12.04%
Investment Advisor/Hedge Fund
4.24%
Hedge Fund
3.90%
Venture Capital
1.72%
Individual Investor
0.58%
Research Firm
0.15%
Bank and Trust
0.01%
其他
61.59%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
2023Q2
173
10.09M
52.77%
+1.83M
2023Q1
168
6.01M
55.14%
-976.73K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Gilead Sciences Inc
5.32M
12.84%
--
--
Apr 21, 2025
683 Capital Management LLC
1.45M
3.5%
+99.90K
+7.40%
Mar 31, 2025
Acadian Asset Management LLC
1.28M
3.09%
+1.06M
+470.43%
Mar 31, 2025
Beigene Ltd
1.22M
2.93%
+1.22M
--
Oct 31, 2024
The Vanguard Group, Inc.
1.18M
2.84%
-15.38K
-1.29%
Mar 31, 2025
Monaco asset management S.A.M.
1.05M
2.53%
+844.13K
+410.02%
Mar 31, 2025
Simplify Asset Management Inc
950.97K
2.29%
+4.93K
+0.52%
Mar 31, 2025
HealthCare Ventures LLC
697.23K
1.68%
+20.91K
+3.09%
Apr 21, 2025
Key Client Fiduciary Advisors, LLC
388.72K
0.94%
+27.47K
+7.60%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
公告日期
类型
比率
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
